New hope for advanced breast cancer patients who stopped responding to earlier therapies
NCT ID NCT07299825
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called A166 in people with HER2-positive breast cancer that has spread and no longer responds to certain previous treatments. About 40 adults aged 18 to 75 will receive A166 to see if it shrinks tumors or slows the disease. The goal is to find a better option for patients who have run out of effective therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER 2 POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Henan Provincial Cancer Hospital
RECRUITINGZhenzhou, Henan, 450000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could routine brain scans catch hidden cancer spread?
- Smart combo therapy aims to boost remission in HER2+ breast cancer
- Biosimilar for breast cancer tracked in real-world study
- New drug cocktail aims to wipe out breast cancer before surgery
- New combo therapy aims to boost breast cancer treatment before surgery
- New MRI dye could spot brain tumors sooner in cancer patients